US20130177953A1

US20130177953A1 - Recombinant process for the production of r-aromatic alpha hydroxy ketones

Info

Publication number: US20130177953A1
Application number: US13/640,672
Authority: US
Inventors: Santosh Noronha; Praveen Kumar Agrawal; P. Jayadeva Bhat
Original assignee: Indian Institute of Technology Bombay
Current assignee: Indian Institute of Technology Bombay
Priority date: 2010-04-13
Filing date: 2010-08-02
Publication date: 2013-07-11
Also published as: BR112012025948A2; WO2011128907A1; EP2558585A1; EP2558585B1

Abstract

A process for preparation of (R)-aromatic α-hydroxy ketones of formula (I), said process occurring in strain(s) of yeast expressing a recombinant pyruvate decarboxylase, having cysteine residues at positions 221 and 222 of PDC1, an isoenzyme of said pyruvate decarboxylase, substituted with glutamate and alanine respectively such that the said mutation being in the regulatory site of pyruvate decarboxylase, selectively favours carboligation reaction over decarboxylation.

Description

FIELD OF INVENTION

The present invention relates to a process for the production of (R)-aromatic α-hydroxy ketones of formula (I). In particular, the present invention relates to a process for enhanced production of said (R)-aromatic α-hydroxy ketones of formula (I) in a genetically modified yeast strain having mutation in the regulatory site of Pyruvate decarboxylase.

BACKGROUND OF THE INVENTION

(R)-phenylacetylcarbinol ((R)-PAC) an optically active compound, is an important aromatic α-hydroxy ketone formed by the acyloin condensation of pyruvic acid with benzaldehyde by the enzyme pyruvate decarboxylase. This enzyme is widely distributed in yeasts, fungi, plants and is also found in some bacteria. (R)-PAC is a precursor and a key intermediate for preparation of compounds such as ephedrine and pseudo-ephedrine, which are two major pharmaceutically active agents found in a wide range of pharmaceutical formulations. These compounds are adrenergic sympathomimetic agents and have anti-histamine activity. Pseudo-ephedrine is useful as a nasal decongestant and is found as an ingredient in cough and cold capsules, sinus medications, nose sprays, nose drops and allergy and hay fever medications. Ephedrine is useful as a topical nasal decongestant, a treatment for mild forms of shock (CNS stimulant) and as a bronchodilator. (R)-PAC has also found application as a chiral auxiliary.
For many decades, (R)-PAC has been obtained by biotransformation of benzaldehyde by pyruvate decarboxylase (PDC) using various species of fermenting yeast. PDCs used in such biotransformation are mainly isolated from Saccharomyces cerevisiae, Kluyveromyces marxianus, Neurospora crassa, Candida utilis, and Rhizopus javanicus (O. P. Ward, A. Singh, Curr. Opin. Biotechnol. 2000, 11, 520;) and the bacterium Zymomonas mobilis, (B. Rosche, V. Sandford, M. Breuer, B. Hauer, P. L. Rogers, J. Mol. Catal. B: Enzym. 2002, 19-20, 109).
Efforts have been made for in vitro production of (R)-PAC by isolating PDC. This process has an advantage of getting product in high purity with negligible formation of by-products. However, these procedures suffer from one or other drawback such as the cost of enzyme production, stability of enzyme, need external addition of pyruvate and cost of immobilization. Consequently, in vitro processes are not economically feasible. The whole cell classical biotransformation process itself suffers from several drawbacks, such as formation of by-products (mostly benzyl alcohol) by different reducing systems in the yeast (S. Panke, M. Wubbolts, Curr. Opin. Chem. Biol. 2005, 9, 188), as seen in scheme below.
Most of the literatures concerning the synthesis of (R)-PAC by fermenting yeast deal with yield optimization. The available literature suggests that the current yeast transformation of benzaldehyde to (R)-PAC is inefficient and yeast productivity is low. The yeast cannot be used for multiple batches because (R)-PAC production drops with increased exposure to the substrates and to the end product. In addition there exist several reports of enhanced productivity as a consequence of optimization of nutrients, solvent or reactor conditions. There is a general consensus that a high concentration of yeast cells is needed to obtain even relatively low levels of PAC.
Most literature approaches to (R)-PAC process enhancement involve improving PDC levels. PDC activity was found to be rate limiting factor in (R)-PAC production by S. carlsbergensis (Vojtisek, V. & Netrval, J. Effect of pyruvate decarboxylase activity and of pyruvate concentration on the production of 1-hydroxy-1-phenylpropanone in Saccharomyces carlsbergensis. Folia Microbiol (Praha), 1982, 27, 173-177), and low PDC concentration was identified as a cause of low R-PAC production in S. cerevisiae (Mahmoud, W.; El-Sayed, A.-H. & Coughlin, R. Biotechnology Bioeng, 1990, 36, 55-63).
Various methods for induction/increase of. PDC activity have been implemented by fermentation optimization techniques (Tripathi, C. K.; Agarwal, S. C.; Bihari, V.; Joshi, A. K. & Basu, S. K. Production of (L)-phenylacetylcarbinol by free and immobilized yeast cells. Indian J Exp Biol, 1997, 35, 886-889, Culik et al, 1984 Czech Patent No: 222941). However, an increase in PDC activity by overexpression of the enzyme does not necessarily imply a better (R)-PAC process; various groups have over expressed PDC1 in vivo towards increasing ethanol levels (a consequence of decarboxylation reaction) and found that the increase in PDC activity in vivo does not increase ethanol levels in S. cerevisiae (Schaaff I.; Heinisch, J. & Zimmermann, F. K. Yeast, 1989, 5, 285-290, and van Hoek, P.; Flikweert, M. T.; van der Aart, Q. J.; Steensma, H. Y.; van Dijken, J. P. & Pronk, J. T. Appl Environ Microbiol, 1998, 64, 2133-214). Ethanol levels do increase when PDC is expressed in other organisms with no/less PDC activity (e.g E. coli and Bacillus sp). In a (R)-PAC production process, increasing PDC would increase both decarboxylation and carboligation activities.
There are further reports in the literature of specific structural modifications of PDC1 (one of the six isoenzymes of PDC) from S. cerevisiae and Z. mobilis. The enzyme from Zymomonas is capable of accepting an acetaldehyde as a substrate (instead of pyruvate) and incorporating it into (R)-PAC. Since acetaldehyde is substantially cheaper than pyruvate, there has been focus on modifying the bacterial enzyme via a site-directed mutagenesis approach. Nevertheless, the conversion efficiencies with the bacterial enzyme are low and consequently the yeast enzyme is currently considered superior for (R)-PAC synthesis, by either in vivo or in vitro routes. Bruhn et al report a modification which influences the carboligation reaction. A mutation is carried out at the active site of ZmPDC, where the tryptophan residue at position 392 is replaced by alanine. Such a mutation influences the decarboxylase/carboligase activity and stability of pyruvate decarboxylase. and increases carboligation activity by four fold and also decreases decarboxylation activity by 2 fold.
ScPDC1 is a homotetramer coded for by a 1692 base pair nucleotide sequence. ScPDC1 exhibits Hill kinetics with respect to pyruvate whereas ZmPDC exhibits Michaelis-Menten type of behavior. Yeast PDC has two pyruvate binding sites: a regulatory site and an active site. The regulatory site must be bound by a pyruvate before the active site takes up a second pyruvate and catalyzes it to acetaldehyde during the (normal) decarboxylation reaction. Thiamine diphosphate and Magnesium dependent PDC catalyzes two types of reactions: decarboxylation (C—C bond breakage), and also carboligation (C—C bond formation). In the PAC process, PDC uses active site bound acetaldehyde (“active aldehyde”) obtained by the decarboxylation of the pyruvate, and carboligates it to externally provided benzaldehyde (S. Panke, M. Wubbolts, Curr. Opin. Chem. Biol. 2005, 9, 188). However, the overall efficiency of the pyruvate utilization for the carboligation reaction remains very low, with a very ^-small proportion of the pyruvate being converted to the desired product, and the bulk of pyruvate undergoing decarboxylation to acetaldehyde.
There are four cysteine residues present in the sequence of PDC1: C69, C152, C221, and C222. C69 is buried deep inside the molecule, whereas the other three are accessible to solvent. Hubser et al., Hubner, G., Konig, S., Schellenberger, A. 1988 Biomedica Biochimica Acta 47 (1), pp. 9-18, Konig, S., Hubner, G., Schellenberger, A. 1990 Biomedica Biochimica Acta 49 (6), pp. 465-471) proposed that the cysteine residues are responsible for the hysteretic substrate activation behaviour of pyruvate decarboxylase.
Based on site directed mutagenesis and steady-state kinetic experiments, Baburina et. al. (Baburina, I., Gao, Y., Hu, Z., Hohmann, S., Furey, W., & Jordan, F. (1994) Biochemistry 33, 5630-5635) proposed that C221 is a primary binding site of the regulatory substrate molecule. A substrate analogue study with pyruvamide by Schnieder et. al (Lu, G.; Dobritzsch, D.; Baumann, S.; Schneider, G. & Konig g, S. Eur J Biochem, 2000, 267, 861-868) identified that a nitrogen atom of the side chain of H115 from the O-subunit and the carboxyl group of E477 from the C-subunit are the key catalytic residues. These amino acid residues were already identified as important catalytic residues by site-directed mutagenesis in PDC from both Z. mobilis and S. cerevisiae (Chang, A. K.; Nixon, P. F. & Duggleby, R. G. Biochem J, 1999, 339 (Pt 2), 255-260, and Schenk, G.; Leeper, F. J.; England, R.; Nixon, P. F. & Duggleby, R. G. Eur J. Biochem, 1997, 248, 63-71)(Duggleby et al. (Baburina, I., Li, H Bennion, B., Furey, W., & Jordan, F. (1998) Biochemistry 37, 1235-1244.).
Wei et al. (Wen Wei, Min Liu, and Frank Jordan; Biochemistry, 2002, 41 (2), pp 451-461) reported work on C221S/C222A and C221E/C222A variants in which a negative charge is built onto the C221 side chain, to better mimic the effect of a pyruvate molecule covalently bonded to C221 as a thiohemiketal. These variants are nearly as active as the wild type enzyme, yet show no substrate activation. Their Results indicate that the effect of C221 substitutions on transition states starts with the binding of the first substrate to the enzyme and terminates with the decarboxylation step. Studies carried out by Wei et al are directed towards characterizing the decarboxylation reaction. It has been observed that this specific variant is practically as active as wild type PDC1 and the only difference is in the alleviation of substrate activation. These observations are confined to characterizing the enzyme in vitro and not in vivo. This is relevant in the sense that several reports exist which describe modifications to an enzyme where in vitro, activity changes are manifest, but where there is no impact on in vivo pathway behavior.
Specifically, attempts to modify PDC towards enhancing decarboxylation rates and improving in vivo ethanol production in yeast, have failed.
There have also been studies on mutations at the active site which affect the extent of carboligation. Jordan et al have created various other mutations to study the PDC1. They have conducted studies on the impact of mutations brought about in the active site on carboligation reactions and have shown that there was improvement in carboligation following mutation of E477Q and D28A, D28N (Sergienko, E. A. & Jordan, F. Biochemistry, 2001, 40, 7369-7381). Subsequently they have also analyzed these mutants for R-PAC formation (Baykal, A.; Chakraborty, S.; Dodoo, A. & Jordan, F. Bioorg Chem, 2006, 34, 380-393). The C221 mutant as suggested by Wei et al has lower activity compared to WTPDC1 and therefore it was never a good choice for increasing carboligation.
Also, there have been no in vivo studies where wild type or mutant forms of PDC have been expressed to enhance the production of (R)-PAC. The only in vivo experimentation reported relates to efforts to increase decarboxylation (ethanol) levels. Although Bruhn et al teaches increasing the activity of the enzyme by a factor of 4 with regards to carboligation, such teachings cannot be extrapolated, because in S. cerevisiae, an alanine residue is already present at the same position in the active site as taught in Bruhn et. al. Moreover, wild type yeast Pdcs have 20 fold higher carboligation activity when compared to wild type ZmPDC (Bruhn et al.). Therefore ZmPDC, even with a 4 fold higher carboligation as a consequence of an active site mutation, is still not equivalent to yeast Pdcs.
Moreover, Shin et al (Production of L-phenylacetylcarbinol (L-PAC) from benzaldehyde using partially purified pyruvate decarboxylase (PDC). Biotechnol Bioeng. 49, 52-62.) clearly discloses that higher PDC activity is not necessary for higher (R)-PAC production. Rogers et al (Rogers, P. L.; Shin, H. S. & Wang, B. Biotransformation for L-ephedrine production. Adv Biochem Eng Biotechnol, 1997, 56, 33-59) also carried out studies to show that higher PDC activity increased the initial rate of (R)-PAC production but that a higher yield could not be assured.
Accordingly, there exists a need in the art for metabolic engineering approaches towards increasing L-PAC levels in vivo by modifying PDC such that the carboligation reaction is selectively preferred over the decarboxylation reaction.
Surprisingly, it has now been found that a PDC with improved synthesis capacity with respect to the formation of (R)-PAC can be obtained which has a relatively high selectivity for the carboligation reaction as compared to the decarboxylation reaction, thus increasing the production of (R)-aromatic α-hydroxy ketones in a genetically modified strain of S. cerevisiae, with PDC mutated at its regulatory site.
The present inventors have found that accumulation of higher levels of (R) aromatic α-hydroxy ketones in a mutated S. cerevisiae strain expressing a C221 E/C222A variant of ScPDC1 overcomes drawback found in the prior art.

OBJECTS OF THE INVENTION

It is an object of the present invention to provide a novel process for enhanced. production of (R)-aromatic α-hydroxy ketones.
It is another object of the present invention to provide a process for enhanced production of (R)-aromatic α-hydroxy ketones in genetically modified strain of yeast, preferably S. cerevisiae, having a polypeptide that possesses pyruvate decarboxylase activity.
It is yet another object of the present invention to provide a process for enhanced production of (R)-aromatic α-hydroxy ketones in genetically modified strain of yeast, preferably S. cerevisiae, having mutations at positions 221 and 222 in the regulatory site of the pyruvate decarboxylase in order to favour the carboligation reaction over decarboxylation.
It is another object of the present invention to provide a process for enhanced biotransformation to (R)-aromatic α-hydroxy ketones by overexpressing any functional PDC in any yeast species, preferably S. cerevisiae.
It is another object of the present invention to provide a process for enhanced biotransformation to (R)-aromatic α-hydroxy ketones by overexpressing ScPDC (1, 5 and 6).
It is another object of the present invention to provide a process for enhanced biotransformation to (R)-aromatic α-hydroxy ketones by overexpressing any PDC with mutation at the regulatory site (to remove substrate activation).

SUMMARY OF THE INVENTION

An aspect of the present invention is to provide a process for preparation of (R)-aromatic α-hydroxy ketones of formula (I), said process occurring in strain(s) of yeast expressing a recombinant pyruvate decarboxylase, having cysteine residues at positions 221 and 222 of PDC1, an isoenzyme of pyruvate decarboxylase, substituted with glutamate and alanine respectively such that the said mutation being in the regulatory site of pyruvate decarboxylase, selectively favours carboligation reaction over. decarboxylation.
Another aspect of the present invention is to provide a process for preparation of (R)-aromatic α-hydroxy ketones of formula (I), said process occurring in strain(s) of yeast expressing a recombinant polypeptide having pyruvate decarboxylase activity, having cysteine residues at position 221 of PDC5 and PDC6, are substituted with glutamate at position 222 of PDC5 is substituted with alanine such that the said mutation being in the regulatory site of the enzyme, which selectively favours carboligation reaction over decarboxylation. PDC5 and PDC6 are isoenzymes of said polypeptide.
Yet another aspect of the present invention is to provide a process for preparation of (R)-aromatic α-hydroxy ketones of formula (I), said process occurring in strain(s) of yeast expressing a recombinant polypeptide having pyruvate decarboxylase activity, wherein the strain is preferably Saccharomyces sp and more preferably Saccharomyces cerevisia.

BRIEF DESCRIPTION OF FIGURES

FIG. 1: A comparison of in vivo ethanol formation in wild type strains of S. cerevisiase overexpressing PDC1 (BY-P1, open circles) and vector control pGPD (BY-GPD, closed circles).

FIG. 2: In vitro comparison of decarboxylation rates, PDC1 (close circle) and PDC1-C221E/C222A (open circle).

FIG. 3: In vitro comparison of R-PAC formation rates, PDC1 (close circle) and PDC1-C221E/C222A (open circles).

FIG. 4: Carboligation activity measured in cell free extract of Wild type control strain (B-G) and PDC1 over expressed strain (B-P1)

FIG. 5: Decarboxylation activity measured in cell free extract of Wild type control strain (B-G) and PDC1 over expressed strain (B-P1)

FIG. 6: (R)-PAC production in a wild type laboratory strain (B) of S. cerevisiae by PDC1 (B-P1)

FIG. 7: (R)-PAC production in a wild type laboratory strain (B) of S. cerevisiae by PDC5 (B-P5)

FIG. 8: (R)-PAC production in a wild type laboratory strain (B) of S. cerevisiae by PDC6 (B-P6)

FIG. 9: (R)-PAC production in a wild type laboratory strain (B) of S. cerevisiae by PDC1 double mutant (B-PD)

FIG. 10: (R)-PAC production in a wild type laboratory strain (Y) of S. cerevisiae by PDC1 (Y-P1).

FIG. 11: (R)-PAC production in a wild type laboratory strain (Y) of S. cerevisiae by PDC5 (Y-P5).

FIG. 12: (R)-PAC production in a wild type laboratory strain (Y) of S. cerevisiae by PDC6 (Y-P6)

FIG. 13: (R)-PAC production in a wild type laboratory strain (Y) of S. cerevisiae by PDC1 double mutant (Y-PD)

FIG. 14: (R)-PAC production in a pdc null strain (D) of S. cerevisiae by PDC1 (P1), PDC5 (P5), PDC6 (P6) and PDC1 double mutant (PD)

FIG. 15: Production of (R)-aromatic α-hydroxy ketones of formula (I) by employing acetaldehyde which is not achievable by employing PDCs from wild type(WT) yeast.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a method for enhancing (R)-aromatic α-hydroxy ketones of formula (I) productivity by way of a recombinant (mutant variant of) S. cerevisiae wherein the gene of the key enzyme involved in the biotransformation (Pyruvate decarboxylase) is modified in S. cerevisiae. The (R)-aromatic α-hydroxy ketones in the present invention is preferably (R)-phenylacetylcarbino; ((R)-PAC).
In a (R)-PAC production process, increasing PDC would increase both decarboxylation and carboligation activities. It is known that PDC is not rate limiting for decarboxylation (ethanol level does not change) but according to the present inventors it is limiting for carboligation (R-PAC) purposes. Since carboligation requires additional mechanism steps, the decarboxylation reaction may be expected to be several times faster than carboligation.
Specifically, attempts to modify PDC towards enhancing decarboxylation rates and improving in vivo ethanol production in yeast, have failed and the present inventors have also verified the same the result of which is illustrated in FIG. 1. Rate of pyruvate utilization by wild-type and mutant PDC1. Equal amount of purified PDCs were assayed for decarboxylation activity in vitro. The rate of pyruvate utilization was calculated for both enzymes and compared. As evident form FIG. 2, the mutant has a lowered decarboxylation rate.
It has also been verified by the present inventors that the C221E mutation does not increase carboligation activity in in vitro conditions. FIG. 3 illustrates a comparative graph between a wild type S. cerevisiae and mutant ScPDC1. Equal amounts of both proteins were assayed for R-PAC formation against a fixed concentration of benzaldehyde (100mM) and varying concentration of pyruvate (0 to 150 mM). Mutant PDC1 has lower R-PAC formation rate in vitro.
The table below provides a comparison of catalytic efficiencies of PDCs for decarboxylation and carboligation from FIGS. 2 and 3.


	Vmax (decarboxylation)	Vmax (carboligation)
PDC	μmol/min/mg	mM R-PAC/min

PDC1	35.3	0.14
PDC-C221E/C222A	7.6	0.07

It is evident from the above table that a 4 fold decrease was observed in the decarboxylation reaction rate while carboligation rate has decreased only 2 fold. This mutation therefore selectively favors carboligation over decarboxylation.
Six genes for PDC have been identified in S. cerevisiae, of which three (Pdc1, 5, and 6) are catalytically active and the rest have role in regulation of PDC activity. These three active isoenzymes can be prepared by the known,gene sequence from the database by recombinant methods. S. cerevisiae genome sequence is known and is available at the yeast genome database (www.yeastgenome.org). Information about the desired genes can be obtained from this database. Based on sequences, specific primers can be designed to amplify the respective genes. (Molecular cloning, Maniatis 1989)
Mutations may lead to conformational changes in the enzyme. But all conformational changes brought about by mutations are not similar and they may produce different effects. Some mutation affects decarboxylation while others may change the carboligation reaction C221E mutant when studied in vitro does not favor carboligation, but when expressed in vivo results in higher R-PAC production. According to the inventors this could be because of increased intracellular pyruvate levels. This enzyme has decreased decarboxylation activity in vitro and this likely reduces pyruvate utilization in vivo. Consequently an elevated level of pyruvate likely exists which benefits the progress of the carboligation reaction (which, at least in vitro, is affected less by the mutation). Another possible aspect is that the decarboxylated pyruvate may be less easily given off by the mutant, facilitating a condensation with the exogenously added benzaldehyde).
Isolation procedure for the target gene (primers used for amplification of the gene) and characterization of gene was carried out according to the procedure available on www.yeastgehome.org.
The PCR amplification, construction of vectors and transformation of PDC1, PDC5 and PDC6 were carried out according to the standard PCR protocol available at Molecular Cloning by E. F. Fritsch, J. Sambrook, T. Maniatis 1989.
PDC1, PDC5 and PDC6 were modified at substrate regulatory site (Cys221) by site-directed mutagenesis. Single cysteine (Cys221) or both cysteine (Cys221 and Cys222) were replaced with Glu221 or Glu221/Ala222. Mutation of C221 E and C221A were done similar to Wei et al., using standard protocol for Site-directed mutagenesis (Quikchange™ Site directed mutagenesis protocol adapted from Stratagene).
Further, it has been observed that expression of these modified enzymes in a Pdc null strain produced even higher R-PAC than that obtained by over expression of single native Pdc.
The invention is now demonstrated by way of non limiting illustrative examples.

EXAMPLE 1

To establish the concept of improved biotransformation by changing PDC activity, these enzymes were expressed in yeast strains grown on a medium selected from one of the following—minimal (defined media), YPD (yeast extract, peptone, dextrose) and a commercial feed stock like molasses. Plasmid for expression of PDC1, PDC5, PDC6 and PDC-221/222 were transformed into various yeast strains.
First, enhancement of PDC activity was confirmed by estimation of total activity in cell free extract of recombinant strains. Both decarboxylation and carboligation activities were measured in cell free extract. FIGS. 4 and 5 illustrate the carboligation and decarboxylation activity measured in cell free extract of Wild type (B-GPD) and PDC1 over expressed strain (B-PDC1) respectively.
After confirmation of increased PDC activity these strains were tested for biotransformation. Biotransformation experiments were conducted at lab scale under controlled conditions and were compared to results with the parent strain. Over-expression of these enzymes leads to increase in (R)-aromatic α-hydroxy ketones of formula (I) production compared to the parent (non-recombinant) strain. This increase in (R)-aromatic α-hydroxy ketones of formula (I) production was from 10% to 100% with different enzymes, the highest being with the PDC-C221E/C222A mutant. Effect of PDC activity on biotransformation by these enzymes was determined in various strains.

EXAMPLE 2

A wild type strain (B) of S. cerevisiae was transformed with plasmid expressing PDC1, PDC5, PDC6 and PDC1 mutant.
FIGS. 6 to 9 describe increase in the (R)-PAC by over expression of different PDC enzymes and PDC1 mutant.

EXAMPLE 3

To establish that the effect of PDC activity is strain independent, these enzymes were also expressed in another wild-type strain (Y) of S. cerevisiae.
FIGS. 10 to 13 describe similar increases in the levels of (R)-PAC by over expression of different PDC enzymes and the PDC1 mutant in this alternate host.

EXAMPLE 4

Examples 1, 2 and 3 indicated the benefit of increaseing PDC activity in cells. To eliminate the effect of genomic PDC and to study the contribution of recombinant/modified PDC on biotransformation, a strain of S. cerevisiae with reduced/null PDC activity was selected for the experiments. Expression of these enzymes in this strain leads to very high production of (R)-PAC.
It was observed that the (R)-PAC production was high in all the strains expressing the mutant form of PDC1; and was highest when this form was expressed in the strain with reduces/null activity (FIG. 14).
The present invention by way of over-expression of ScPDCs provide the following advantages:

- Improves biotransformation in all S. cerevisiae strains. Site directed mutagenesis results in further improvement in the process.
- Production of (R)—aromatic α-hydroxy ketones of formula (I) by employing acetaldehyde which is not achievable by employing the wild type (WT) PDCs of wild type (WT) yeast as illustrated in FIG. 15.

Claims

1. A process for preparation of (R)-aromatic α-hydroxy ketones in a commercial feedstock like sugarcane molasses, of formula (I), said process occurring in strain(s) of yeast expressing a recombinant pyruvate decarboxylase, having cysteine residues in the regulatory sites of PDC1, PDC5 and PDC6, an isoenzyme of said pyruvate decarboxylase, substituted with glutamate and alanine respectively such that the said mutation being in the regulatory site of pyruvate decarboxylase.

2. The process as claimed in claim 1 wherein the improvement for PDC production is in the level of about 57 mM (˜61% biotransformation efficiency w.r.t benzaldehyde) along with feedstock conservation as a consequence of lower pyruvate wastage.

3. The process as claimed in claim 1 wherein the cysteine residues are at position 221 and 222 of PDC1.

4. The process as claimed in claim 1 wherein the enzyme is being expressed through a plasmid or integrated genomically.

5. The process as claimed in claim 1 wherein R is H or CH₃;

wherein R′ is phenyl or optionally substituted phenyl wherein the substituents are selected from the group C_1-3alkyl, C_1-3alkoxy, F, CI, Br, I, OH, NH₂, CN and NR₁R₂, wherein R₁and R₂can be independently H or (C_1-4) alkyl and the said C_1-3alkyl can be further substituted by a substituent chosen from F, CI, Br, I and OH and also pyridine, thiophene, furan, napthaldehyde and their substituents.

6. The process as claimed in claim 1 comprising isolating a polypeptide encoded by the nucleic acid sequence of PDC1 from yeasts and substituting the amino acid at the substrate regulatory site at positions 221 and 222.

7. The process as claimed in claim 1 where the strain(s) of yeast expressing a polypeptide having pyruvate decarboxylase activity, comprising a polypeptide encoded by the nucleic acid sequence of PDC5.

8. The process as claimed in the claim 6 where the cysteine at 221 is replaced with glutamic acid in PDC5.

9. The process as claimed in claim 4 where the strain(s) of yeast having a polypeptide that possesses pyruvate decarboxylase activity, comprising a polypeptide encoded by the nucleic acid sequence of PDC 6.

10. The process as claimed in claim 8, where the cysteine at 221 positions in PDC6 is replaced with glutamic acid.

11. The process as claimed in claim 1, where the recombinant PDC is introduced in a wild type strain of yeast species (Saccharomyces sp, Kluyveromyces sp, Pichia sp, Hansenula sp.

12. The process as claimed in claim 1, where the recombinant PDC is introduced in a native or recombinant strain of yeast with reduced/null Pdc activity. (Saccharomyces sp, Kluyveromyces sp, Pichia sp, Hansenula sp).

13. The process for preparation of (R)-aromatic α-hydroxy ketones of formula (I) as claimed in claims 1 to 7 wherein the (R)-aromatic α-hydroxy ketone is preferably (R)-phenylacetylcarbinol ((R)-PAC).